Navigation Links
Epeius in Medical News

Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival

... SAN MARINO, Calif., June 22 /PRNewswire/ -- epeius Biotechnologies ( www.epeiusbiotech.com ) stuns ...d, said Dr. Erlinda M. Gordon, Medical Director of epeius Biotechnologies. Yet the progressive development ...ndard in terms of evaluating efficacy. About epeius Biotechnologies Rexin-G is commercially availab...

Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer

... SAN MARINO, Calif., June 17 /PRNewswire/ -- epeius Biotechnologies ( www.epeiusbiotech.com ) announ...says Dr. Erlinda Maria Gordon, Medical Director of epeius Biotechnologies, "and an important validation of o...d integrity of the clinical development program of epeius Biotechnologies. "It took years of sustained effor...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009

... SAN MARINO, Calif., May 18 /PRNewswire/ -- epeius Biotechnologies ( www.epeiusbiotech.com ) today ...l solid tumors in the Republic of the Philippines, epeius Biotech is conducting a series of advanced Phase I..., May 30, 2009 at 5:00 p.m. EST/EDT. About epeius Biotechnologies ...

FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.

... SAN MARINO, Calif., Nov. 5 /PRNewswire/ -- epeius Biotechnologies Corporation announced today that t...ls of Rexin-G are centered in San Marino CA, where epeius Biotechnologies Corporation has its headquarters, ...nvestigator (PI) for these clinical trials. About epeius Biotechnologies ...
Epeius in Medical Technology

ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe an...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies

... SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- epeius Biotechnologies announced today the results of Pha...oft tissue sarcoma and osteosarcoma. About epeius Biotechnologies epeius Biotechnologies Corporation is a privately held bi...

Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)

... SAN MARINO, Calif., May 29 /PRNewswire/ -- epeius Biotechnologies ( http://www.epeiusbiotech.com ) announced today the result...ation about Rexin-G, on-going clinical trials in the USA and abroad, and/or epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erl...

TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)

... SAN MARINO, Calif., May 27 /PRNewswire/ -- epeius Biotechnologies ( http://www.epeiusbiotech.com ) announced today that the r...exin-G, Reximmune-C, on-going clinical trials in the USA and abroad, and/or epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erl...

TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

... SAN MARINO, Calif., May 22 /PRNewswire/ -- epeius Biotechnologies announced today the promising results of an on-going United...ation about Rexin-G, on-going clinical trials in the USA and abroad, and/or epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erl...

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer

...ens SAN MARINO, Calif., April 21 /PRNewswire/ -- epeius Biotechnologies Corporation announced today that I...at are resistant to standard chemotherapy. About epeius Biotechnologies epeius Biotechnologies Corporation is a privately held bi...

Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine

... SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- epeius Biotechnologies Corporation announced today their ...ivo Solutions to Gene Delivery," the scientists of epeius Biotechnologies might have attended. *(LOGO 72dp...ually do, should continue to do just that. About epeius Biotechnologies ...

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

... 04, 2007 /PRNewswire/ -- (SEND2PRESS NEWSWIRE) -- epeius Biotechnologies Corporation today announced the pu...rds of Dr. Frederick L. Hall, President and CEO of epeius -- "In each and every cancer patient extends their...nging hard science gently to the bedside." About epeius Biotechnologies ...
Epeius in Biological Technology

Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial

SAN MARINO, Calif., Feb. 12 /PRNewswire/ -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clini...

Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery

SAN MARINO, Calif., Oct. 6 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled "Targeting metastatic cancer from the inside: A new g...

FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas

SAN MARINO, Calif., July 9 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of all soft tissue sarcomas. This latest approval is the third clinical indicatio...

The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers

... SAN MARINO, Calif., June 9 /PRNewswire/ -- epeius Biotechnologies' Rexin-G is the world's smallest hero ( www.epeiusbiotech....now embodied in the tumor-targeted anti-cancer agent, Rexin-G, developed by epeius Biotechnologies. Rexin-G is currently approved for the treatment of all so...

REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)

... SAN MARINO, Calif., Jan. 20 /PRNewswire/ -- epeius Biotechnologies ( www.epeiusbiotech.com ) announced the results of a U.S. P...ment of all solid tumors that are resistant to standard chemotherapy. epeius Biotechnologies Corporation is a privately held biopharmaceutical company d...

Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate

... SAN MARINO, Calif., Dec. 16 /PRNewswire/ -- epeius Biotechnologies Corporation, a leader in tumor-tar... single-agent-efficacy, as well as overall safety, epeius Biotech continues to lead the field of clinical ge...the USA for several types of cancer. About epeius Biotechnologies ...

Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan

... SAN MARINO, Calif., Oct. 29 /PRNewswire/ -- epeius Biotechnologies Corporation announced today the ex...s-sponsored protocols C07-104 and C07-105. About epeius Biotechnologies epeius Biotechnologies Corporation is a privately held bi...

Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal

... SAN MARINO, Calif., Sept. 15 /PRNewswire/ -- epeius Biotechnologies Corporation today announced that R... the second tumor-targeted agent in development by epeius Biotechnologies, describing Reximmune-C as an immu...s. The JNCI article is well worth reading. About epeius Biotechnologies ...

Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma

... SAN MARINO, Calif., July 8 /PRNewswire/ -- epeius Biotechnologies Corporation today announced that R...idates the unique clinical development strategy of epeius Biotechnologies: that is, to demonstrate the profo...es. About Rexin-G Rexin-G, the lead product of epeius Biotechnologies, is the first in a series of tumor...

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer

... SAN MARINO, Calif., May 19 /PRNewswire/ -- epeius Biotechnologies announced today the results of an on-going Phase I/II study...ation about Rexin-G, on-going clinical trials in the USA and abroad, and/or epeius pathotropic (disease-seeking) gene delivery systems, please contact Dr. Erl...
Other Tags
(Date:7/13/2014)... July 13, 2014 If Dr. Lawrence Power ... has just launched at http://www.HealthYourself101.com will expand people’s ... , Power has set out to provide a health ... that’s actually – dare we say it? – entertaining to ... Power, “aims to engage the remote learner – the solitary ...
(Date:7/12/2014)... to the new market research report "Security and Surveillance ... - Global Forecasts and Analysis to 2014 - 2020", ... estimated to be $6.08 billion in 2014 and are ... $8.61 billion by 2020. , Browse more than 93 ... pages and in-depth TOC on "Security and Surveillance Radar ...
(Date:7/12/2014)... The Passenger Information System market is estimated to grow ... 2019, at an expected CAGR of 26.5% for the ... infrastructure in North America is well developed and network ... of the region. The growing ridership figures in public ... are driving the North American Passenger Information System market ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... no way to guarantee that a surgical technique used to ... won,t increase the risk of spreading cancer to other parts ... The advisory panel to the Food and Drug Administration also ... laparoscopic power morcellation -- should sign a written consent stating ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The Security ... in 2013 to $3,376.6 million by 2019, at an ... and 2019. The challenges to counter the increasing number ... existence of outdated cyber defense systems in organizations are ... innovating and remodeling their existing architecture to develop better ...
Breaking Medicine News(10 mins):Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
(Date:7/11/2014)... the City of Entiat on Tuesday, July 8, 2014. ... grew to over 1,000 acres by evening. Three outbuildings ... investigation by the Washington Department of Natural Resources. The ... in developing fire control strategies and tactics. Other cooperators ... of Natural Resources, (WA DNR), Bureau of Land Management, ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... Ume University, Sweden, have explored two different ways ... sequence leading to the formation of oxygen molecules ... in the scientific journal Nature Communications . ... day synthetic catalysts for water oxidation, which are ... the direct storage of solar energy in fuels ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
Other Contents